Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| AVXL | 8-K | bearish | 6/10 | Anavex Life Sciences received a Nasdaq delinquency notice on May 20, 2026, for failing to timely file its Form 10-Q for | May 22, 2026 |
| BNTX | 6-K | neutral | 4/10 | BioNTech filed a 6-K announcing its upcoming presentations at the 2026 ASCO Annual Meeting, including new clinical data | May 22, 2026 |
| AVXL | PRESS-RELEASE | bearish | 7/10 | Anavex Life Sciences disclosed a Nasdaq delinquency notice for failing to timely file its Q2 FY2026 Form 10-Q, adding to | May 22, 2026 |
| GTBP | 8-K | bearish | 7/10 | GT Biopharma received a Nasdaq notice granting an additional 180-day compliance period until November 16, 2026, to regai | May 22, 2026 |
| TRAW | 424B5 | bearish | 7/10 | Traws Pharma filed a 424B5 prospectus supplement to increase the ATM offering capacity by up to $3.1M, bringing total po | May 22, 2026 |
| AAPG | 6-K | neutral | 5/10 | Ascentage Pharma filed a 6-K furnishing its third amended and restated memorandum and articles of association (adopted M | May 22, 2026 |
| BCTXL | PRESS-RELEASE | bullish | 7/10 | BriaCell announced positive Phase 2 survival data for Bria-IMT in heavily pre-treated metastatic breast cancer, with med | May 22, 2026 |
| GLAXF | 6-K | neutral | 2/10 | GSK confirmed its Q2 2026 earnings release date of July 28, 2026, along with a schedule of dividend dates for the remain | May 22, 2026 |
| ASMB | 8-K | neutral | 5/10 | Assembly Biosciences announced plans to expand clinical development of ABI-6250, its oral NTCP inhibitor, from chronic h | May 22, 2026 |
| ASMB | PRESS-RELEASE | neutral | 5/10 | Assembly Bio is expanding ABI-6250, an oral NTCP inhibitor in Phase 1a for HDV, into cholestatic liver diseases (PBC/PSC | May 22, 2026 |
| BLRX | 6-K | bullish | 6/10 | BioLineRx and partner Hemispherian AS announced that two preclinical abstracts on GLIX1, a first-in-class oral TET2 acti | May 22, 2026 |
| ACIU | PRESS-RELEASE | bullish | 6/10 | AC Immune presented Phase 1 data at the 2026 TDP43 Summit showing its TDP-43 PET tracer ACI-19626 detects higher uptake | May 22, 2026 |
| LYB | PRESS-RELEASE | neutral | 2/10 | LyondellBasell declared a quarterly dividend of $0.69 per share, payable June 8, 2026. This is a routine capital return | May 22, 2026 |
| PALI | EFFECT | neutral | 4/10 | Palisade Bio's $300M universal shelf registration (File No. 333-295815) became effective on May 21, 2026, enabling the c | May 22, 2026 |
| PEPG | EFFECT | bearish | 7/10 | PepGen's S-3 shelf registration (File No. 333-296016) became effective on May 21, 2026, enabling the company to sell up | May 22, 2026 |
| ACHV | EFFECT | bearish | 6/10 | The SEC declared effective Achieve Life Sciences' S-3 registration statement (File No. 333-295798) on May 21, 2026, cove | May 22, 2026 |
| GRTX | 425 | bullish | 7/10 | Galera Therapeutics filed a Rule 425 communication reposting Obsidian Therapeutics' LinkedIn announcement of positive Ph | May 22, 2026 |
| BNTX | PRESS-RELEASE | neutral | 5/10 | BioNTech announced new clinical data for pumitamig (Phase 2/3 ROSETTA Lung-02 in 1L NSCLC) and gotistobart (Phase 2 PRES | May 22, 2026 |
| NGEN | PRESS-RELEASE | bearish | 6/10 | NervGen Pharma priced a $60M underwritten public offering of 24M common shares and warrants, with shares at $2.50 and wa | May 21, 2026 |
| RPRX | CLUSTER | neutral | 2/10 | Two insiders at Royalty Pharma sold a combined $883K in open-market transactions over a one-week window. The sales repre | May 21, 2026 |
| LIMN | PRESS-RELEASE | bearish | 8/10 | Liminatus Pharma received a Nasdaq delisting notice after failing to regain compliance with the $50M market value of lis | May 21, 2026 |
| AAPG | PRESS-RELEASE | neutral | 4/10 | Ascentage Pharma announced that six abstracts from its clinical studies were selected for presentation at the 2026 ASCO | May 21, 2026 |
| NBIX | CLUSTER | neutral | 4/10 | Two directors sold $40.2M in NBIX shares ($2.36M and $37.82M) within days of Neurocrine's $2.9B acquisition of Soleno Th | May 21, 2026 |
| NKTR | CLUSTER | bearish | 5/10 | Two top executives at Nektar Therapeutics (CEO Howard Robin and Chief R&D Officer Jonathan Zalevsky) sold a combined $42 | May 21, 2026 |
| BIIB | PRESS-RELEASE | bearish | 7/10 | Biogen and Denali announced that the Phase 2b LUMA study of BIIB122 in early-stage Parkinson's disease failed to meet it | May 21, 2026 |
| DNLI | PRESS-RELEASE | bearish | 7/10 | Denali Therapeutics and Biogen announced that the Phase 2b LUMA study of BIIB122 in early-stage Parkinson's disease fail | May 21, 2026 |
| CATX | PRESS-RELEASE | neutral | 4/10 | Perspective Therapeutics announced it will present updated data on three clinical-stage programs ([²¹²Pb]VMT-α-NET, [²¹² | May 21, 2026 |
| NBIX | CLUSTER | bearish | 5/10 | Two NBIX directors sold shares totaling ~$40.8M following the closing of the $2.9B Soleno acquisition, representing mode | May 21, 2026 |
| ZNTL | PRESS-RELEASE | bullish | 6/10 | Zentalis announced positive Phase 1b data for azenosertib plus paclitaxel in platinum-resistant ovarian cancer, with 39% | May 21, 2026 |
| ZNTL | 8-K | bullish | 6/10 | Zentalis Pharmaceuticals announced Phase 1b MUIR trial data for azenosertib plus paclitaxel in platinum-resistant ovaria | May 21, 2026 |